ClinicalTrials.gg
Active, not recruitingNCT05284747EVOLVE-MIUpdated Nov 9, 2026

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

A Phase 4 interventional study of Evolocumab and Routine Lipid Management in Cardiovascular Disease, Myocardial Infarction and Stroke, sponsored by Amgen. Active, not recruiting at 120 sites in 3 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Updated Nov 9, 20263 sites added3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6,019
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).

02

Conditions studied

  • Cardiovascular Disease
  • Myocardial Infarction
  • Stroke
  • Coronary Revascularization

Keywords

  • Acute Myocardial Infarction
  • Cardiovascular Disease
  • Stroke
  • Coronary revascularization
  • Evolocumab
  • STEMI
  • NSTEMI
  • Heart Attack
  • Pragmatic
03

In context

Cardiovascular Diseases

5,372 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's enrollment of 6,019 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to 18 years
  • Hospitalized for primary reason of NSTEMI or STEMI due to presumed atherosclerotic disease

Exclusion criteria

Exclusion Criteria:

  • Participants requiring invasive hemodynamic and/or vasopressor/inotropic support at the time of screening
  • Participants with elevated biomarkers of myocardial injury due to secondary/nonatherosclerotic etiology (eg, sepsis, atrial fibrillation, vasospasm, decompensated heart failure, uncontrolled hypertension, stress induced cardiomyopathy)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6,019 participants (actual)

Study arms

  • Experimental
    Evolocumab + Routine Lipid Management

    Participants will receive open-label evolocumab every 2 weeks (Q2W) plus routine lipid management.

    Drug: Evolocumab · Drug: Routine Lipid Management

  • Active comparator
    Routine Lipid Management

    Participants will receive routine lipid management per standard of care (SoC).

    Drug: Routine Lipid Management

Interventions

  • Evolocumab will be provided as a single-dose, prefilled autoinjector pen (AI/pen) for fixed dose subcutaneous (SC) injection.

    Also known as: Repatha, AMG 145

  • DrugRoutine Lipid Management

    Routine lipid management therapies will be administered at the discretion of the investigator per SoC.

06

What researchers measure

Primary outcomes

  1. Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and all-cause death

    Time frame: From Baseline to End of Study (Approximately 3.5 Years)

Secondary outcomes

  1. Percentage Change From Baseline in LDL-C

    Percent LDL-C change from baseline to 12 weeks in a subset of approximately 300 randomly selected participants.

    Time frame: From Baseline to Week 12

  2. Percentage Change From Baseline in LDL-C

    Percent LDL-C change from baseline to 52 weeks in a subset of approximately 300 randomly selected participants.

    Time frame: From Baseline to Week 52

  3. Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and cardiovascular death

    Time frame: From Baseline to End of Study (Approximately 3.5 Years)

  4. Time to the First Occurrence of the Composite of Myocardial Infarction, Ischemic Stroke, any Arterial Revascularization Procedure, and All-Cause Death

    Time frame: From Baseline to End of Study (Approximately 3.5 Years)

  5. Total Myocardial Infarctions Events

    Time frame: From Baseline to End of Study (Approximately 3.5 Years)

  6. Total Arterial Revascularization Procedures

    Time frame: From Baseline to End of Study (Approximately 3.5 Years)

  7. Total Ischemia-driven Coronary Revascularization Procedures

    Time frame: From Baseline to End of Study (Approximately 3.5 Years)

  8. Total Ischemic Strokes

    Time frame: From Baseline to End of Study (Approximately 3.5 Years)

  9. Time to Cardiovascular Death

    Time frame: From Baseline to End of Study (Approximately 3.5 Years)

  10. Time to All-Cause Death

    Time frame: From Baseline to End of Study (Approximately 3.5 Years)

07

Study locations

120 sites

Showing the first 100 of 120 sites across 3 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for May 2027, 55 months after the start.

Of 113 phase 4 interventional studies under Cardiovascular Diseases, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 64. This study's planned 55 months is above that.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2022
First posted
Mar 17, 2022
StartActual
Oct 26, 2022
Primary completionEst.
May 29, 2027
CompletionEst.
May 29, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (2 Brazil, 1 United States)
  • Pima Heart and Vascular Clinical Research · Tuscon, United States
  • Instituto do coracao da Faculdade de Medicina da Universidade de Sao Paulo - InCor · São Paulo, Brazil
  • Hospital Israelita Albert Einstein · São Paulo, Brazil
Show 3 removed
  • Pima Heart and Vascular Clinical Research · Tucson, United States
  • Instituto do coracao da Faculdade de Medicina da Universidade de Sao Paulo - InCor · São Paulo, Brazil
  • Hospital Israelita Albert Einstein · São Paulo, Brazil
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    3 sites added, 3 sites removed
    Show 3 added (2 Brazil, 1 United States)
    • Pima Heart and Vascular Clinical Research · Tuscon, United States
    • Instituto do coracao da Faculdade de Medicina da Universidade de Sao Paulo - InCor · São Paulo, Brazil
    • Hospital Israelita Albert Einstein · São Paulo, Brazil
    Show 3 removed
    • Pima Heart and Vascular Clinical Research · Tucson, United States
    • Instituto do coracao da Faculdade de Medicina da Universidade de Sao Paulo - InCor · São Paulo, Brazil
    • Hospital Israelita Albert Einstein · São Paulo, Brazil
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05284747
Lead sponsor
Amgen
Collaborators
Colorado Prevention Center
Responsible party
Sponsor
First posted
Mar 17, 2022
Start date
Oct 26, 2022
Primary completion
May 29, 2027 (estimated)
Completion
May 29, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion